Free Trial

David Dai Analyst Performance

Analyst at Sanford C. Bernstein

David Dai is a stock analyst at Sanford C. Bernstein focused in the medical sector, covering 17 publicly traded companies. Over the past year, David Dai has issued 31 stock ratings, including buy and hold recommendations. While full access to David Dai's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Dai's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
34 Last 6 Years
Buy Recommendations
69.70% 23 Buy Ratings
Companies Covered
17 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy69.7%23 ratings
Hold30.3%10 ratings
Sell0.0%0 ratings

Out of 33 total stock ratings issued by David Dai at Sanford C. Bernstein, the majority (69.7%) have been Buy recommendations, followed by 30.3% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
88.2% of companies on NASDAQ
15 companies
NYSEAMERICAN
5.9% of companies on NYSEAMERICAN
1 company
NYSE
5.9% of companies on NYSE
1 company

David Dai, an analyst at Sanford C. Bernstein, currently covers 17 companies listed on NASDAQ, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
14 companies
82.4%
Computer and Technology
2 companies
11.8%
Consumer Discretionary
1 company
5.9%

David Dai of Sanford C. Bernstein specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology and Consumer Discretionary companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
12 companies
70.6%
SEQPT - WAFER FAB
1 company
5.9%
SURGICAL & MEDICAL INSTRUMENTS
1 company
5.9%
AUDIO/VIDEO PRD
1 company
5.9%
MED - DRUGS
1 company
5.9%
INTERNET SERVICES
1 company
5.9%

David Dai's Ratings History at Sanford C. Bernstein

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
5/13/2026Lower Price Target$20.12$37.00Buy
ASML Holding N.V. stock logo
ASML
ASML
4/23/2026Reiterated Rating$1,454.97Buy
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
4/15/2026Downgrade$15.24$15.00Neutral
ASML Holding N.V. stock logo
ASML
ASML
3/26/2026Boost Price Target$1,393.89$1,971.00Buy
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
3/23/2026Initiated Coverage$1.23Neutral
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3/18/2026Boost Price Target$4.95$8.00Buy
Sony Corporation stock logo
SONY
Sony
3/17/2026Reiterated Rating$21.67$22.00Market Perform
Sony Corporation stock logo
SONY
Sony
3/16/2026Downgrade$20.92$22.00Market Perform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
3/13/2026Reiterated Rating$8.61$15.00Buy
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
3/5/2026Boost Price Target$4.16$4.00Neutral
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3/3/2026Boost Price Target$88.16$128.00Buy
ASML Holding N.V. stock logo
ASML
ASML
2/25/2026Reiterated Rating$1,497.80Buy
ASML Holding N.V. stock logo
ASML
ASML
1/29/2026Set Price Target$1,422.92$1,911.00
ASML Holding N.V. stock logo
ASML
ASML
1/22/2026Boost Price Target$1,360.09$1,642.00Outperform
ASML Holding N.V. stock logo
ASML
ASML
1/16/2026Reiterated Rating$1,358.57Buy
Sony Corporation stock logo
SONY
Sony
1/14/2026Reiterated Rating$24.41$30.00Outperform
Sony Corporation stock logo
SONY
Sony
1/14/2026Set Price Target$24.41$30.00Outperform
ASML Holding N.V. stock logo
ASML
ASML
1/5/2026Upgrade$1,163.78Buy
ASML Holding N.V. stock logo
ASML
ASML
1/4/2026Set Price Target$1,163.78$1,528.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
12/17/2025Reiterated Rating$102.44Buy
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
12/4/2025Upgrade$97.28Hold
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
12/2/2025Reiterated Rating$17.97$57.00Buy
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
11/14/2025Boost Price Target$12.35$16.00Buy
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
11/6/2025Boost Price Target$103.43$117.00Neutral
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11/4/2025Boost Price Target$14.98$38.00Buy
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10/31/2025Boost Price Target$98.17$132.00Buy
Merus N.V. stock logo
MRUS
Merus
9/30/2025Downgrade$93.67$97.00Neutral
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
7/15/2025Lower Price Target$9.26$35.00Buy
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
7/10/2025Lower Price Target$12.67$26.00Buy
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
7/1/2025Initiated Coverage$21.28$30.00Buy
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
6/5/2025Boost Price Target$128.10$129.00Neutral
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
5/16/2025Downgrade$1.76$2.00Neutral
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
5/12/2025Lower Price Target$7.89$24.00Buy